Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by pabalooon Mar 16, 2021 5:14pm
200 Views
Post# 32810236

Still Waiting??

Still Waiting??

What are these hospital products Cipher is referring to?? I have never seen any material numbers on there financials. Losing 25% of revenue next year at best. If it goes back to half a buck it's a buy. Fully valued at .90 cents do the math. 25 million market cap. 7 million cash 2 acne products worth 10 million trevyent worth 2 million a fungal cream 2 million and various products that are worth a combined 2-3 million if sold. Also if they don't sell Absorica to sun the value in 3 years is zero. It will have no future against the LD version owned fully by Sun under there agreement. You can't find a higher value here period like I said fully valued.Take 25 percent off for management inability to run the company and it's actually over valued. But Cameco it will be 40 dollars in 2 years.

<< Previous
Bullboard Posts
Next >>